CN114685520B - Tri-fused ring compound and pharmaceutical composition and application thereof - Google Patents
Tri-fused ring compound and pharmaceutical composition and application thereof Download PDFInfo
- Publication number
- CN114685520B CN114685520B CN202111602260.2A CN202111602260A CN114685520B CN 114685520 B CN114685520 B CN 114685520B CN 202111602260 A CN202111602260 A CN 202111602260A CN 114685520 B CN114685520 B CN 114685520B
- Authority
- CN
- China
- Prior art keywords
- compound
- mmol
- reaction
- pharmaceutical composition
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 179
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 25
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 8
- 201000011510 cancer Diseases 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 abstract description 25
- 108010056274 polo-like kinase 1 Proteins 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 16
- 239000003112 inhibitor Substances 0.000 abstract description 11
- 230000005764 inhibitory process Effects 0.000 abstract description 11
- 239000002207 metabolite Substances 0.000 abstract description 9
- 229940002612 prodrug Drugs 0.000 abstract description 9
- 239000000651 prodrug Substances 0.000 abstract description 9
- 239000012453 solvate Substances 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- 101100464293 Caenorhabditis elegans plk-1 gene Proteins 0.000 abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 113
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 66
- 238000006243 chemical reaction Methods 0.000 description 57
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
- 235000019439 ethyl acetate Nutrition 0.000 description 38
- 238000004949 mass spectrometry Methods 0.000 description 37
- 238000004809 thin layer chromatography Methods 0.000 description 35
- 230000015572 biosynthetic process Effects 0.000 description 33
- 238000003786 synthesis reaction Methods 0.000 description 32
- -1 cyano, hydroxy, amino Chemical group 0.000 description 31
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
- 239000007787 solid Substances 0.000 description 26
- 239000000243 solution Substances 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 239000012074 organic phase Substances 0.000 description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 19
- 125000004432 carbon atom Chemical group C* 0.000 description 18
- 239000003480 eluent Substances 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 102100030708 GTPase KRas Human genes 0.000 description 15
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 15
- 239000003208 petroleum Substances 0.000 description 15
- 125000000217 alkyl group Chemical group 0.000 description 14
- 238000001035 drying Methods 0.000 description 14
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 14
- 125000006413 ring segment Chemical group 0.000 description 14
- 238000010898 silica gel chromatography Methods 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 11
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 9
- 125000004429 atom Chemical group 0.000 description 9
- 239000012267 brine Substances 0.000 description 9
- 229940125904 compound 1 Drugs 0.000 description 9
- 125000005842 heteroatom Chemical group 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 125000000753 cycloalkyl group Chemical group 0.000 description 7
- 125000004404 heteroalkyl group Chemical group 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 101000767160 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Intracellular protein transport protein USO1 Proteins 0.000 description 6
- 125000001931 aliphatic group Chemical group 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 5
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 229940125782 compound 2 Drugs 0.000 description 5
- 229940126214 compound 3 Drugs 0.000 description 5
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- OUBORTRIKPEZMG-UHFFFAOYSA-N INT-2 Chemical compound Nc1c(ncn1-c1ccc(F)cc1)C(=N)C#N OUBORTRIKPEZMG-UHFFFAOYSA-N 0.000 description 4
- 101001060278 Xenopus laevis Fibroblast growth factor 3 Proteins 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 125000000000 cycloalkoxy group Chemical group 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000010189 synthetic method Methods 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 description 3
- QHLVBNKYJGBCQJ-UHFFFAOYSA-N 1-(2-hydroxyethyl)-8-[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)anilino]-4,5-dihydropyrazolo[4,3-h]quinazoline-3-carboxamide Chemical compound C1CN(C)CCN1C1=CC=C(OC(F)(F)F)C(NC=2N=C3C=4N(CCO)N=C(C=4CCC3=CN=2)C(N)=O)=C1 QHLVBNKYJGBCQJ-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 description 3
- 102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- JYFJNCCRKBBRKZ-UHFFFAOYSA-N chembl194764 Chemical compound C=1C=CC=C(F)C=1CCN1C(=O)C(CC)=C(C)N=C1C1=CC=CC=C1O JYFJNCCRKBBRKZ-UHFFFAOYSA-N 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical group CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000011632 Caseins Human genes 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 2
- 108091006094 GTPase-accelerating proteins Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 101150105104 Kras gene Proteins 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- 125000006677 (C1-C3) haloalkoxy group Chemical group 0.000 description 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- 125000006411 1-propenylene group Chemical group [H]\C(*)=C(\[H])C([H])([H])[H] 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- 238000003727 ADP Glo Kinase Assay Methods 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 101100404726 Arabidopsis thaliana NHX7 gene Proteins 0.000 description 1
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010069755 K-ras gene mutation Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000713862 Moloney murine sarcoma virus Species 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 208000008900 Pancreatic Ductal Carcinoma Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 108010029869 Proto-Oncogene Proteins c-raf Proteins 0.000 description 1
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
- 102100031426 Ras GTPase-activating protein 1 Human genes 0.000 description 1
- 108050004017 Ras GTPase-activating protein 1 Proteins 0.000 description 1
- 229910019891 RuCl3 Inorganic materials 0.000 description 1
- 108700022176 SOS1 Proteins 0.000 description 1
- 101100197320 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RPL35A gene Proteins 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 102100032929 Son of sevenless homolog 1 Human genes 0.000 description 1
- 101150100839 Sos1 gene Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- GXVKHKJETWAWRR-UHFFFAOYSA-N a805143 Chemical compound C1CCNC1.C1CCNC1 GXVKHKJETWAWRR-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 229910001392 phosphorus oxide Inorganic materials 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- BIXNGBXQRRXPLM-UHFFFAOYSA-K ruthenium(3+);trichloride;hydrate Chemical compound O.Cl[Ru](Cl)Cl BIXNGBXQRRXPLM-UHFFFAOYSA-K 0.000 description 1
- YBCAZPLXEGKKFM-UHFFFAOYSA-K ruthenium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Ru+3] YBCAZPLXEGKKFM-UHFFFAOYSA-K 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229910052717 sulfur Chemical group 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a tricyclic compound, a pharmaceutical composition and application thereof. The compound is a compound shown in a formula I, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a tautomer thereof, or a hydrate thereof, or a solvate thereof, or a metabolite thereof, or a prodrug thereof, wherein R 1~R3, L, X, Y and Z groups are defined as in the specification. The compound and the pharmaceutical composition containing the same have good PLK1 enzyme inhibition activity, so the compound and the pharmaceutical composition can be used as PLK1 inhibitors and can be used for preparing medicines for treating and/or preventing diseases such as cancers over-expressed by PLK 1.
Description
Technical Field
The invention belongs to the field of pharmaceutical chemistry, and particularly relates to a tricyclic compound, a pharmaceutical composition containing the compound and application of the compound in the field of medicines.
Background
Proteins expressing the normal KRAS gene (murine sarcoma virus oncogene) play an important role in normal tissue signal transduction. Mutation of the KRAS gene due to single amino acid substitutions, particularly single nucleotide substitutions, is responsible for activating the mutation, which is an essential step in many cancer developments. The muteins produced are involved in a variety of malignancies, including lung adenocarcinoma, mucous adenocarcinoma, pancreatic ductal carcinoma, and colorectal carcinoma. Similar to other members of the Ras family, KRAS proteins are gtpases and are involved in many signal transduction pathways.
KRAS acts as a molecular on/off switch that, once turned on, recruits and activates proteins necessary for growth factor and other receptor signaling, such as c-Raf and PI-3 kinase. Normal KRAS binds GTP in the active state and has an inherent enzymatic activity, i.e. cleaves the terminal phosphate of a nucleotide, converting it into GDP. After converting GTP to GDP, KRAS is turned off. The conversion is generally slow but can be significantly accelerated by auxiliary proteins of the GTPase Activating Protein (GAP) class, such as RasGAP. In turn, KRAS may bind to proteins of the guanine nucleotide exchange factor (GEF) class, such as SOS1, which forces release of the bound nucleotides. Subsequently, KRAS binds GTP present in the cytoplasm and GEF is released from ras-GTP. In mutant KRAS, its gtpase activity is directly removed, such that KRAS is constitutively active. Mutant KRAS are generally characterized by: mutation of codons 12, 13, 61 or a mixture thereof.
PLK1 is a serine/threonine kinase consisting of 603 amino acids and having a molecular weight of 66kDa, and is an important regulator of the cell cycle. In particular, PLK1 is important for mitosis and is involved in the formation and changes of the mitotic spindle and the activation of CDK/cyclin complexes during the M phase of the cell cycle.
The viability of cancer cells harboring mutant KRAS is known to be dependent on Polo-like kinase 1 (PLK 1), and silencing PLK1 has been shown to result in cell death containing mutant KRAS. Thus, compounds that inhibit PLK1 are useful in the treatment of cancers caused by KRAS mutations.
Disclosure of Invention
The invention aims to provide a tricyclic compound used as a PLK1 inhibitor with a novel structure, which has good inhibition activity on tumor cells, good patentability and wide drug development prospect.
In a first aspect, the present invention provides a compound of formula I, or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, metabolite, or prodrug thereof, wherein
Wherein,
L is- (CH 2)m-(A)p-(CH2)n -, wherein A is selected from oxygen, CR 10 or NR 10, m, p and n are independently any integer from 0 to 3;
X, Y and Z are each independently selected from CR 4 or N;
r 1 is selected from hydrogen, C 1-C6 alkyl, C 1-C6 heteroalkyl, C 2-C6 alkenyl, C 2-C6 alkynyl, C 3-C8 cycloalkyl, C 3-C8 heterocycloalkyl, C 3-C8 cycloalkoxy, or C 3-C8 heterocycloalkoxy, and wherein each of said alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkoxy, and heterocycloalkoxy is optionally substituted with at least 1R 5;
R 2 is selected from cyano 、P(=O)(CH3)2、N=S(=O)(CH3)2、S(=O)(=NH)CH3、SO2NR6R7、NR6-COR7、NR6-CO-NR7、CO-OR6 or CO-NR 6R7;
R 3 is selected from C 6-C10 aryl, 5 to 6 membered monocyclic heteroaryl, or 9 to 10 membered bicyclic heteroaryl, and wherein each of said aryl, monocyclic heteroaryl, and bicyclic heteroaryl is optionally substituted with up to 5R 8;
R 4 and R 5 are each independently selected from hydrogen, halogen, cyano, hydroxy, amino, C 1-C6 alkyl, C 3-C8 cycloalkyl, C 3-C8 heterocycloalkyl, C 1-C3 alkoxy, or C 1-C6 haloalkyl, each optionally substituted with at least 1R 9.
R 6 and R 7 are each independently selected from hydrogen, C 1-C8 alkyl, C 3-C6 cycloalkyl or C 3-C8 heterocycloalkyl, or R 6 and R 7 together with the nitrogen atom to which they are attached form C 3-C8 cycloalkyl or C 3-C8 heterocycloalkyl, and wherein each of said alkyl and cycloalkyl is optionally substituted with at least 1R 9;
R 8 is independently selected from hydrogen, halogen, cyano, hydroxy, amino, C 1-C6 alkyl, C 1-C6 heteroalkyl, C 2-C6 alkenyl, C 2-C6 alkynyl, C 3-C8 cycloalkyl, C 3-C8 heterocycloalkyl, C 3-C8 cycloalkoxy, or C 3-C8 heterocycloalkoxy, and wherein the alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkoxy, and heterocycloalkoxy are each optionally substituted with at least 1R 9;
Each R 9 is independently selected from hydrogen, halogen, cyano, hydroxy, amino, carbamoyl, C 1-C6 alkyl, C 1-C6 heteroalkyl, C 3-C8 cycloalkyl, 3 to 14 membered heterocycloalkyl, C 1-C3 alkoxy, C 1-C3 haloalkoxy, C 6-C10 aryl, 5 to 6 membered monocyclic heteroaryl, or 9 to 10 membered bicyclic heteroaryl, and wherein each of the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, alkoxy, haloalkoxy, aryl, monocyclic heteroaryl bicyclic heteroaryl is optionally substituted with at least 1R 10;
The heteroatoms or heteroatom groups contained in the heteroalkyl, heterocycloalkyl, heterocycloalkoxy, heteroaryl groups in R 1 to R 9 are each independently selected from -C(=O)N(R10)-、-N(R10)-、-NH-、-N=、-O-、-S-、-C(=O)O-、-C(=O)-、-C(=S)-、-S(=O)-、-S(=O)2- and-N (R 10)C(=O)N(R10) -, and the number of heteroatoms or heteroatom groups are each independently selected from 1, 2 and 3;
each R 10 is independently selected from hydrogen, chloro, fluoro, cyano, hydroxy, amino, isopropyl, cyclopropyl, methyl, difluoromethyl, trifluoromethyl, methoxy, trifluoromethoxy, ethoxy, 2-difluoroethoxy, 2-trifluoroethoxy and phenyl.
Preferably, it is a compound as shown in any one of formulas I-1, I-2, I-3, I-4, I-5, I-6, I-7, I-8 or I-9,
Wherein o is independently any integer from 0 to 5.
More preferably, it is a compound as shown in any one of the formulas I-1-1, I-2-1, I-3-1, I-4-1, I-5-1, I-6-1, I-7-1, I-8-1 or I-9-1,
More preferably, the present invention provides specific compounds as shown in formula I, I-1, I-2, I-3, I-4, I-5, I-6, I-7, I-8, I-9, I-1-1, I-2-1, I-3-1, I-4-1, I-5-1, I-6-1, I-7-1, I-8-1 or I-9-1 having the structural formula:
In a second aspect, the invention provides a pharmaceutical composition comprising a compound as shown in formula I, I-1, I-2, I-3, I-4, I-5, I-6, I-7, I-8, I-9, I-1-1, I-2-1, I-3-1, I-4-1, I-5-1, I-6-1, I-7-1, I-8-1 or I-9-1, or one or more pharmaceutically acceptable salts, hydrates, solvates, stereoisomers, tautomers, metabolites or prodrugs thereof.
Preferably, the pharmaceutical composition further comprises at least one pharmaceutically acceptable excipient.
In a third aspect, the invention provides the use of a compound as shown in formula I, I-1, I-2, I-3, I-4, I-5, I-6, I-7, I-8, I-9, I-1-1, I-2-1, I-3-1, I-4-1, I-5-1, I-6-1, I-7-1, I-8-1 or I-9-1, or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, metabolite or prodrug thereof, or a pharmaceutical composition comprising the same, in the manufacture of a medicament for the prevention and/or treatment of a disease caused by overexpression of PLK 1.
In a fourth aspect, the invention provides the use of a compound as shown in formula I, I-1, I-2, I-3, I-4, I-5, I-6, I-7, I-8, I-9, I-1-1, I-2-1, I-3-1, I-4-1, I-5-1, I-6-1, I-7-1, I-8-1 or I-9-1, or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, metabolite or prodrug thereof, or a pharmaceutical composition comprising the same, for the preparation of a PLK1 inhibitor drug.
In a fifth aspect, the invention provides the use of a compound as shown in formula I, I-1, I-2, I-3, I-4, I-5, I-6, I-7, I-8, I-9, I-1-1, I-2-1, I-3-1, I-4-1, I-5-1, I-6-1, I-7-1, I-8-1 or I-9-1, or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, metabolite or prodrug thereof, or a pharmaceutical composition comprising the same, in the manufacture of a medicament for the treatment and/or prophylaxis of cancer.
Preferably, the cancer is any one or more of hematological tumor, pancreatic cancer, colorectal cancer and lung cancer.
In a sixth aspect, the present invention provides a method for preventing and/or treating a disease or disorder caused by overexpression of PLK1, comprising administering to a subject in need thereof a prophylactically and/or therapeutically effective amount of a compound as shown in formula I, I-1, I-2, I-3, I-4, I-5, I-6, I-7, I-8, I-9, I-1-1, I-2-1, I-3-1, I-4-1, I-5-1, I-6-1, I-7-1, I-8-1 or I-9-1, or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, metabolite or prodrug thereof or a pharmaceutical composition comprising the same.
The invention provides novel PLK1 inhibitor compounds which not only have good PLK1 enzyme inhibition activity, but also can obviously reduce ERK phosphorylation in KRAS mutant cancer cell lines and have excellent anti-tumor activity on KRAS mutant cancer cells.
Compared with the prior art, the invention has the following beneficial effects:
The invention provides a series of tricyclic compounds with novel structures, and related enzyme and cell activity tests prove that the compounds have excellent cell proliferation inhibition activity, and in vitro experiments show that the IC 50 value of cell proliferation reaches nM level, so that the compounds can be well applied to various tumors. In particular, the compounds of the invention can significantly reduce ERK phosphorylation in KRAS mutant cancer cell lines, and have excellent antitumor activity on KRAS mutant cancer cells. Is suitable for preparing PLK1 inhibitor for preventing and/or treating diseases or symptoms related to PLK1 activation, such as cancers (including but not limited to blood tumor, pancreatic cancer, colorectal cancer and lung cancer).
Detailed Description
General terms and definitions
Unless stated to the contrary, the terms used in the present invention have the following meanings.
"Alkyl" refers to saturated aliphatic hydrocarbon groups, including straight and branched chain groups of 1 to 20 carbon atoms, which may be, for example, straight and branched chain groups of 1 to 18 carbon atoms, 1 to 12 carbon atoms, 1 to 8 carbon atoms, 1 to 6 carbon atoms, or 1 to 4 carbon atoms. In the present invention, "alkyl" may be a monovalent, divalent or trivalent group. Non-limiting examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1-dimethylpropyl, 1, 2-dimethylpropyl, 2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1, 2-trimethylpropyl, 1-dimethylbutyl, 1, 2-dimethylbutyl, 2-dimethylbutyl, 1, 3-dimethylbutyl, 2-ethylbutyl, and various branched isomers thereof, and the like. Non-limiting examples also include, but are not limited to, methylene, ethylene, propylene, butylene, and various branched isomers thereof. In addition, in the present invention, "alkyl" may be optionally substituted or unsubstituted.
"Alkoxy" refers to an "-O-alkyl" group, where "alkyl" is defined above.
"Alkenyl" refers to unsaturated aliphatic hydrocarbon groups, including straight and branched chain groups of 1 to 20 carbon atoms and at least 1 carbon-carbon double bond, and may be, for example, straight and branched chain groups of 1 to 18 carbon atoms, 1 to 12 carbon atoms, 1 to 8 carbon atoms, 1 to 6 carbon atoms, or 1 to 4 carbon atoms. In the present invention, "alkenyl" may be a monovalent, divalent or trivalent group. Non-limiting examples include, but are not limited to, vinyl (-ch=ch 2), propen-1-yl (-ch=ch-CH 3), propen-2-yl (-C (CH 3)=CH2), buten-1-yl (-ch=ch-CH 2-CH3), buten-2-yl (-C (C 2H5)=CH2), 1-methylpropen-1-yl (-C (CH 3)=CH-CH3) and various branched isomers thereof, etc. non-limiting examples also include, but are not limited to, 1-vinylidene (=c=ch 2), 1, 2-vinylidene (-ch=ch-), 1-propenylene (=c=ch-CH 3), 1, 2-propenylene (-ch=c (CH 3) -), 1, 3-propenylene (-ch=ch-CH 2 -) and various branched isomers thereof.
"Alkynyl" refers to unsaturated aliphatic hydrocarbon groups, including straight and branched chain groups of 1 to 20 carbon atoms and at least 1 carbon-carbon triple bond, and may be, for example, straight and branched chain groups of 1 to 18 carbon atoms, 1 to 12 carbon atoms, 1 to 8 carbon atoms, 1 to 6 carbon atoms, or 1 to 4 carbon atoms. In the present invention, "alkynyl" may be a monovalent, divalent or trivalent group. Non-limiting examples include, but are not limited to, ethynylPropynyl groupButynyl groupPentynyl groupAnd various branched isomers thereof. Non-limiting examples also include, but are not limited to, ethynylenePropynyl groupButynyl groupAnd various branched isomers thereof. In addition, in the present invention, "alkynyl" may be optionally substituted or unsubstituted.
"Heteroalkyl" refers to saturated aliphatic hydrocarbon groups, including straight and branched chain groups of 2 to 20 atoms, such as may be straight and branched chain groups of 2 to 18 atoms, 2 to 12 atoms, 2 to 8 atoms, 2 to 6 atoms, or 2 to 4 atoms, where one or more atoms are heteroatoms selected from nitrogen, oxygen, or S (O) m (where m is 0, 1, or 2) and the remainder are carbon. In the present invention, "heteroalkyl" may be a monovalent, divalent or trivalent group. Non-limiting examples include, but are not limited to, methoxymethyl (2-oxapropyl), methylthiomethyl (2-thiapropyl), methylaminomethyl (2-aza-propyl), and various branched isomers thereof, and the like. In addition, in the present invention, "heteroalkyl" may be optionally substituted or unsubstituted.
"Cycloalkyl" refers to a saturated or partially unsaturated, mono-or polycyclic aliphatic hydrocarbon group comprising 3 to 12 ring atoms, which may be, for example, 3 to 12, 3 to 10, or 3 to 6 ring atoms (i.e., 3 to 6 membered rings). Non-limiting examples of monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, and the like. In the present invention, "cycloalkyl" may be optionally substituted or unsubstituted.
"Heterocycloalkyl" means a saturated or partially unsaturated, mono-or polycyclic aliphatic hydrocarbon group comprising 3 to 20 ring atoms, which may be, for example, 3 to 16, 3 to 12, 3 to 10 or 3 to 6 ring atoms, wherein one or more of the ring atoms is a heteroatom selected from nitrogen, oxygen or S (O) m (where m is 0, 1 or 2) and the remaining ring atoms are carbon. Preferably the heterocycloalkyl group comprises 3 to 12 ring atoms, of which 1 to 4 ring atoms are heteroatoms, more preferably 3 to 10 ring atoms, most preferably 5 or 6 ring atoms, of which 1 to 4, preferably 1 to 3, more preferably 1 to 2 are heteroatoms. Non-limiting examples of monocyclic heterocycloalkyl groups include, but are not limited to, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, and the like. Non-limiting examples of polycyclic heterocycloalkyl groups include, but are not limited to, a fused, spiro, or bridged heterocycloalkyl group.
"Halogen" means fluorine, chlorine, bromine and iodine, preferably fluorine, chlorine and bromine.
"Haloalkyl" or "haloalkoxy" refers to an alkyl or alkoxy group substituted with one or more halogen atoms, which may be the same or different, examples of preferred alkyl or alkoxy groups include, but are not limited to: trifluoromethyl, trifluoroethyl, trifluoromethoxy.
"Cyano" refers to the "-CN" group.
"Hydroxy" refers to an "-OH" group.
"Amino" refers to the "-NH 2" group.
"Carbamoyl" refers to the "- (c=o) -NH 2" group.
"Aryl" refers to monocyclic, bicyclic, and tricyclic carbocyclic ring systems containing 6 to 14 ring atoms, wherein at least one ring system is aromatic, wherein each ring system contains rings of 3 to 7 atoms and has one or more points of attachment to the remainder of the molecule. Examples include, but are not limited to: phenyl, naphthyl, anthracene, and the like. Preferably, the aryl group is a carbocyclic ring system of 6 to 10 or 6 to 7 ring atoms.
"Heteroaryl" refers to monocyclic, bicyclic, and tricyclic ring systems containing 5 to 14 ring atoms, wherein at least one ring system is aromatic and at least one ring system contains one or more heteroatoms selected from nitrogen, oxygen, and sulfur, wherein each ring system contains a ring of 5 to 7 atoms and has one or more points of attachment to the remainder of the molecule. The term "heteroaryl" may be used interchangeably with the term "heteroaromatic ring" or "heteroaromatic compound". Examples include, but are not limited to: furyl, imidazolyl, 2-pyridyl, 3-pyridyl, thiazolyl, purinyl, and quinolinyl. Preferably, the heteroaryl group is a ring system of 5 to 10 ring atoms.
"Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs or does not. For example, "a heterocyclic group optionally substituted with an alkyl group" means that an alkyl group may be, but is not necessarily, present, and the description includes cases where the heterocyclic group is substituted with an alkyl group and cases where the heterocyclic group is not substituted with an alkyl group.
"Substituted" means that one or more hydrogen atoms, preferably up to 5, more preferably 1 to 3 hydrogen atoms in the group are independently substituted with a corresponding number of substituents.
By "pharmaceutically acceptable salts" is meant salts prepared from the compounds of the present invention with relatively non-toxic acids or bases. When the compounds of the present invention contain relatively acidic functional groups (e.g., carboxyl or sulfonic groups), the base addition salts may be obtained by contacting the free form thereof with a sufficient amount of a base in pure solution or in a suitable inert solvent. Non-limiting examples of pharmaceutically acceptable base addition salts include, but are not limited to, sodium, potassium, ammonium, calcium, magnesium, organic amine salts, or the like. When the compounds of the present invention contain relatively basic functional groups (e.g., amino or guanidino), the acid addition salts may be obtained by contacting the free form with a sufficient amount of an acid in a pure solution or in a suitable inert solvent. Non-limiting examples of pharmaceutically acceptable acid addition salts include, but are not limited to, inorganic acid salts (e.g., hydrochloride, hydrobromide, hydroiodide, nitrate, carbonate, bicarbonate, phosphate, monohydrogen phosphate, dihydrogen phosphate, phosphite, sulfate, bisulfate, etc.), organic acid salts (e.g., acetate, propionate, isobutyrate, malonate, succinate, suberate, maleate, fumarate, citrate, tartrate, lactate, mandelate, benzoate, phthalate, methanesulfonate, benzenesulfonate, p-toluenesulfonate, glucuronate, etc.), and amino acid salts (e.g., arginate, etc.). Specific forms of pharmaceutically acceptable salts can also be found in Berge et al, "Pharmaceutical Salts", journal of Pharmaceutical Science,1977, 66:1-19). Certain specific compounds of the invention contain basic and acidic functionalities that can be converted to either base or acid addition salts. Preferably, the salt is contacted with a base or acid in a conventional manner to isolate the parent compound, thereby regenerating the neutral form of the compound. The parent form of a compound differs from its various salt forms in certain physical properties, such as solubility in polar solvents. According to an embodiment of the present invention, the pharmaceutically acceptable salt of the compound of formula I is preferably an acid addition salt, preferably a hydrochloride, hydrobromide, phosphate or sulfate salt, more preferably a hydrochloride salt.
"Pharmaceutical composition" refers to a pharmaceutically acceptable composition comprising one or more compounds of formula I or a pharmaceutically acceptable form thereof (e.g., salts, hydrates, solvates, stereoisomers, tautomers, metabolites, prodrugs, etc.), as well as other components (e.g., pharmaceutically acceptable excipients).
In the present invention, "pharmaceutically acceptable excipients" refers to auxiliary materials widely used in the field of pharmaceutical production. The main purpose of the use of auxiliary substances is to provide a pharmaceutical composition which is safe to use, stable in nature and/or has specific functionalities, and to provide a method so that the active ingredient can be dissolved at a desired rate after administration of the drug to a subject, or so that the active ingredient is effectively absorbed in the subject to whom it is administered. Pharmaceutically acceptable excipients may be inert fillers or may be functional ingredients that provide some function to the pharmaceutical composition (e.g., to stabilize the overall pH of the composition or to prevent degradation of the active ingredients in the composition). Non-limiting examples of pharmaceutically acceptable excipients include, but are not limited to, binders, suspending agents, emulsifiers, diluents (or fillers), granulating agents, binders, disintegrants, lubricants, anti-adherent agents, glidants, wetting agents, gelling agents, absorption delaying agents, dissolution inhibitors, reinforcing agents, adsorbents, buffers, chelating agents, preservatives, coloring agents, flavoring agents, sweetening agents, and the like.
The pharmaceutical compositions of the present invention may be prepared using any method known to those skilled in the art. For example, conventional mixing, dissolving, granulating, emulsifying, milling, encapsulating, entrapping and/or lyophilizing processes.
In the present invention, the purpose of the pharmaceutical composition is to promote the administration to a living body, facilitate the absorption of an active ingredient, and further exert biological activity. The pharmaceutical compositions of the present invention may be administered by any form including injection (intra-arterial, intravenous, intramuscular, intraperitoneal, subcutaneous), mucosal, oral (oral solid, oral liquid), rectal, inhalation, implantation, topical (e.g. ocular) administration, and the like. Non-limiting examples of oral solid formulations include, but are not limited to, powders, capsules, lozenges, granules, tablets, and the like. Non-limiting examples of liquid formulations for oral or mucosal administration include, but are not limited to, suspensions, tinctures, elixirs, solutions, and the like. Non-limiting examples of topical formulations include, but are not limited to, emulsions, gels, ointments, creams, patches, pastes, foams, lotions, drops or serum formulations. Non-limiting examples of parenteral formulations include, but are not limited to, solutions for injection, dry powders for injection, suspensions for injection, emulsions for injection, and the like. The pharmaceutical compositions of the invention may also be formulated in controlled-or delayed-release dosage forms (e.g. liposomes or microspheres).
Preferably, the compounds of the present invention or pharmaceutical compositions comprising the same are administered orally or intravenously to an individual in need thereof. Depending on the specific circumstances of the subject, other routes of administration may also be employed or even preferred. For example, transdermal administration would be a very important mode of administration for patients with amnesia or irritability to oral medications. In the present invention, the route of administration can be varied or adjusted in any suitable manner to meet the nature of the drug, the convenience of the patient and medical personnel, and other related factors.
The compound or pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, metabolite or prodrug thereof or the pharmaceutical composition containing the compound has excellent PLK1 enzyme inhibition activity and cell proliferation inhibition activity, can be used as a PLK inhibitor, is used for preventing and/or treating diseases or symptoms caused by PLK over-expression, and has good clinical application and medical application. Preferably, non-limiting examples of diseases or conditions caused by PLK1 overexpression are cancers, including but not limited to hematological tumors, pancreatic cancers, colorectal cancers and lung cancers.
The following examples are provided to further illustrate the invention and are not intended to limit the scope of the invention. Various changes and modifications to the specific embodiments of the invention will be apparent to those skilled in the art without departing from the spirit and scope of the invention.
The preparation of the compounds of the present invention may be accomplished by synthetic methods well known to those skilled in the art, including but not limited to the specific embodiments listed below, embodiments formed in combination with other chemical synthetic methods, and equivalent alternatives well known to those skilled in the art, preferred embodiments including but not limited to the examples of the present invention. The known starting materials used in the present invention may be synthesized by methods known in the art or purchased through conventional commercial means (e.g., from Shaohuan chemical technology, beijing coupling technology, etc.). Unless otherwise indicated, the reactions were carried out under argon or nitrogen atmosphere. The hydrogenation reaction is usually vacuumized, filled with hydrogen and repeatedly operated for 3 times. The reaction temperature is room temperature and the temperature range is 20-30 ℃. Monitoring of the progress of the reaction may be accomplished by synthetic methods well known to those skilled in the art, including but not limited to Thin Layer Chromatography (TLC). Thin layer chromatography silica gel plates using Qingdao ocean GF254 silica gel plates, the developer system includes but is not limited to A: methylene chloride and methanol systems; b: petroleum ether and ethyl acetate system, and the volume ratio of the solvent can be adjusted according to the polarity of the compound.
The isolation and purification of the compounds of the present invention may be accomplished by synthetic methods well known to those skilled in the art, including, but not limited to, column Chromatography (CC), high Performance Liquid Chromatography (HPLC), ultra-high performance liquid chromatography (UPLC), and the like. Column chromatography typically uses Qingdao ocean 200-300 mesh silica gel as a carrier, and eluent systems include, but are not limited to, A: methylene chloride and methanol systems; b: the volume ratio of the petroleum ether to the ethyl acetate can be adjusted according to the polarity of the compound, and a small amount of acidic or alkaline tailing-preventing agent can be added for adjustment. HPLC spectra were determined using an Agilent1200DAD HPLC chromatograph (column: sunfireC18, 150X4.6 mm,5 μm) or a Waters 2695-2996HPLC chromatograph (column: giminiC18, 150X4.6 mm,5 μm).
Structural identification of the compounds of the present invention may be accomplished by methods well known to those skilled in the art, including but not limited to Nuclear Magnetic Resonance (NMR), mass Spectrometry (MS), and the like. NMR spectra were determined using Bruker AVANCE-400 or VarianOxford-300 nuclear magnetic instruments using deuterated dimethyl sulfoxide (DMSO-d 6), deuterated chloroform (CDC 1 3) or deuterated methanol (CD 3 OD), internal standard Tetramethylsilane (TMS), chemical shifts in 10 -6 (ppm). MS spectra were determined using AGILENTSQD (ESI) mass spectrometers (model 6110) or Shimadzu SQD (ESI) mass spectrometers (model 2020).
Preparation of intermediates
Preparation of intermediate INT-1
The preparation method comprises the following steps:
The first step: synthesis of Compound INT-1B
Compound INT-1A (10.0 g,39.2 mmol) was dissolved in dioxane (100.0 mL), and acetic anhydride (4.8 g,47.0 mmol) and triethylamine (7.92 g,78.4 mmol) were added at room temperature to react at 60℃for 18 hours. TLC showed that after the reaction was completed, the reaction mixture was dried by spin-drying, and the residue was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate=10:1 to 1:2 (volume ratio)) to give compound INT-1B (10.4 g, pale yellow solid, yield 89%).
MS(ESI):m/z298.0[M+1]+。
And a second step of: synthesis of Compound INT-1C
Compound INT-1B (2.0 g,6.71 mmol) was dissolved in dioxane (30.0 mL), N-methylpiperazine (671mg,6.71mmol),Cs2CO3(4.4g,13.4mmol),Pd2(dba)3(0.3g,0.34mmol),4,5- bis (diphenylphosphine) -9, 9-dimethylxanthene (0.39 g,0.67 mmol) was added at room temperature, and the reaction mixture was reacted at 95℃for 18 hours under N 2. TLC showed that after the reaction was completed, the reaction mixture was dried by spin-drying and the residue was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate=10:1 to 1:2 (volume ratio)) to give compound INT-1C (2.6 g, pale yellow solid, yield 87%).
MS(ESI):m/z318.1[M+1]+。
And a third step of: synthesis of Compound INT-1D
Compound INT-1C (0.89 g,2.8 mmol) was added to ethanol (10 mL), and then concentrated hydrochloric acid (2.5 mL) was added under ice-bath, and the reaction mixture was reacted at 80℃for 18h. TLC showed that after the reaction was completed, ethanol was turned off, the reaction solution was diluted with water (50 mL), ph=9 was adjusted with aqueous ammonia, extracted with ethyl acetate (15 ml×2), the organic phases were combined, washed with saturated aqueous sodium chloride solution (10 ml×2), the organic phase was dried over anhydrous sodium sulfate, and the organic phase was dried by spin-drying to give compound INT-1D (0.72 g, pale yellow solid, yield 93%).
MS(ESI):m/z276.1[M+1]+。
Fourth step: synthesis of Compound INT-1
Compound INT-1D (0.61 g,2.22 mmol) was added to acetonitrile (10 mL) at room temperature followed by INT-1E (0.35 g,2.89 mmol). The reaction mixture was reacted at 80℃for 18 hours. TLC showed that after the reaction was completed, the reaction solution was spin-dried to give compound INT-1 (0.64 g, brown solid, yield 90%).
MS(ESI):m/z318.2[M+1]+。
Preparation of intermediate INT-2
The preparation method comprises the following steps:
The first step: synthesis of Compound INT-2B
Compound INT-1B (2 g,6.71 mmol) was dissolved in dioxane (30 mL), INT-2A(1.52g,6.71mmol),Cs2CO3(4.4g,13.4mmol),Pd2(dba)3(0.3g,0.34mmol),4,5- bis (diphenylphosphine) -9, 9-dimethylxantheneXanths (0.39 g,0.67 mmol) was added at room temperature, and the reaction mixture was reacted at 95℃for 18 hours under N 2. TLC showed that after the reaction was completed, the reaction mixture was dried by spin-drying and the residue was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate=10:1 to 1:2 (volume ratio)) to give compound INT-2B (2.6 g, pale yellow solid, yield 87%).
MS(ESI):m/z444.2[M+1]+。
And a second step of: synthesis of Compound INT-2C
Compound INT-2B (3.2 g,7.22 mmol) was dissolved in ethyl acetate (15 mL), followed by dropwise addition of 8% strength by mass ethyl acetate hydrochloride (30 mL) and reaction at room temperature for 18h. TLC showed that after completion of the reaction, the reaction solution was dried by spin-drying, the residue was slurried with EtOAc, and the filter cake was filtered to give compound INT-2C (3.0 g, pale yellow solid, purity: 50%, yield 55%).
MS(ESI):m/z344.2[M+1]+。
And a third step of: synthesis of Compound INT-2D
Compound INT-2C (3.0 g,50% purity, 4.37 mmol) was added to dichloromethane (30 mL) and water (10 mL), and 37% aqueous formaldehyde (2.1 g,26.2 mmol) and acetic acid (0.2 mL) were added dropwise over ice and reacted at room temperature for 1h. Sodium cyanoborohydride (0.82 g,13.1 mmol) was then added in portions under ice bath, and the reaction was allowed to proceed at room temperature for 12h. TLC showed that after the reaction was completed, aqueous ammonia was adjusted to ph=9, and the reaction solution was diluted with water (150 mL), extracted with dichloromethane (50 ml×2), extracted, the organic phases were combined, washed with saturated aqueous sodium chloride solution (30 ml×2), the organic phase was dried over anhydrous sodium sulfate, the resulting organic solution was filtered, and the residue after spin-drying was purified by basic alumina column chromatography (eluent: petroleum ether/ethyl acetate=10:1 to 1:2 (volume ratio)) to give compound INT-2D (1.0 g, tan oil, yield 64%).
MS(ESI):m/z358.1[M+1]+。
Fourth step: synthesis of Compound INT-2E
Compound INT-2D (1 g,2.8 mmol) was added to ethanol (10 mL), then concentrated hydrochloric acid (2.5 mL) was added under ice-bath, and the reaction mixture was reacted at 80℃for 18h. TLC showed that after the reaction was completed, ethanol was turned off, the reaction mixture was diluted with water (50 mL), ph=9 was adjusted with aqueous ammonia, extracted with ethyl acetate (15 ml×2), the organic phases were combined, washed with saturated aqueous sodium chloride solution (10 ml×2), the organic phase was dried over anhydrous sodium sulfate, and the resulting organic solution was filtered and dried by spinning to give compound INT-2E (0.8 g, pale yellow solid, yield 91%).
MS(ESI):m/z316.1[M+1]+。
Fifth step: synthesis of Compound INT-2
Compound INT-2F (0.7 g,2.22 mmol) was added to acetonitrile (10 mL) at room temperature followed by INT-1E (0.35 g,2.89 mmol). The reaction mixture was reacted at 80℃for 18 hours. TLC showed that after the reaction was completed, the reaction solution was spin-dried to give compound INT-2 (0.8 g, brown solid, yield 91%).
MS(ESI):m/z358.2[M+1]+。
Preparation and functional verification of target compounds
Example 1: preparation of Compound 1
The structural formula of the compound 1 is as follows:
The synthetic route of compound 1 is:
The specific preparation method of the compound 1 comprises the following steps:
the first step: synthesis of Compound 1C
Compound 1A (3 g,30 mmol) was dissolved in DCM (25 mL), tetrahydropyrrole pyrrolidine (1.1 g,15 mmol) was added under ice-bath and reacted at room temperature for 2h, then 1B (3.6 g,30 mmol) was added under ice-bath and the reaction was reacted at 40℃for 16 h. TLC showed that after the reaction was completed, the reaction mixture was dried by spin-drying, and the residue was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate=10:1 (volume ratio)), to give compound 1C (3.5 g, yellow solid, yield 58%).
MS(ESI):m/z203[M+1]+。
And a second step of: synthesis of Compound 1D
Compound 1C (6.6 g,32.6 mmol) was dissolved in THF (60 mL), liHMDS (49 mL,1M,48.9 mmol) was added dropwise at-60℃under nitrogen, reaction was performed at-60℃for 0.5 and then diethyl oxalate (7.2 g,48.9 mmol) was added dropwise, and the mixture was allowed to react at room temperature for 12h. TLC showed that after the reaction was completed, quenched by pouring ice water, extracted with ethyl acetate, washed with brine, the organic phase was dried over anhydrous sodium sulfate, and the residue was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate=5:1 (volume ratio)) to give compound 1D (3.1 g, yellow solid, yield 31%).
MS(ESI):m/z303[M+1]+。
And a third step of: synthesis of Compound 1E
Compound 1D (2.9 g,9.6 mmol) was added to methanol (25 mL) and acetic acid (5 mL), and 1D-1 (876 mg,9.6 mmol) was added dropwise under ice-bath and reacted at room temperature for 16h. TLC showed that after the reaction was completed, a large amount of solid was precipitated, and the reaction solution was filtered to obtain compound 1E (2.3 g, yellow solid, purity 75%, yield 53%).
MS(ESI):m/z343[M+1]+。
Fourth step: synthesis of Compound 1F
Compound 1E (2.2 g,6.4 mmol) and RuCl3.H2O were added to acetonitrile (30 mL) and water (6 mL), followed by addition of sodium periodate (2.2 g,9.6 mmol) in an ice bath, and the reaction was allowed to react at room temperature for 16h. TLC showed that after the reaction was completed, the reaction solution was diluted with water, extracted with ethyl acetate, washed with brine, the organic phase was dried over anhydrous sodium sulfate, and the residue was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate=1:1 (volume ratio)) to give compound 1F (1.2 g, pale yellow solid, yield 73%).
MS(ESI):m/z255[M+1]+。
Fifth step: synthesis of Compound 1G
Compound 1F (1 g,3.9 mmol) was added to DMF (6 mL) at room temperature, followed by N, N-dimethylformamide dimethyl acetal DMF-DMA (6 mL). The reaction was carried out at 120℃for 2h. TLC showed that after the reaction was completed, compound 1G (1.1G, brown oil, 90% yield) was obtained by spin-drying.
MS(ESI):m/z310[M+1]+。
Sixth step: synthesis of Compound 1H
Compound 1G (1.1G, 3.6 mmol) was added to DMF (10 mL) at room temperature, and compound INT-1 (1.25G, 3.6 mmol) and potassium carbonate (0.98G, 7.1 mmol) were added at room temperature. Then heated to 110℃for reaction 32h. TLC showed that after the reaction was completed, the reaction solution was diluted with water, extracted with ethyl acetate, washed with brine, the organic phase was dried over anhydrous sodium sulfate, and the residue was purified by silica gel column chromatography (eluent: ethyl acetate/methanol=5:1 (volume ratio)), to give compound 1H (0.35 g, yellow solid, yield 17%)
MS(ESI):m/z564[M+1]+。
Seventh step: synthesis of Compound 1
Compound 1H (350 mg,0.06 mmol) was added to a jar containing NMP (5 mL) at room temperature, followed by 7.0M NH 3 in methanol (5 mL). Then heated to 95℃and reacted for 48 hours. TLC showed that after the reaction was completed, the solid precipitated after cooling to room temperature, filtration and washing with ethyl acetate gave compound 1 (200 mg, yellow solid, purity 70%, yield 42%).
MS(ESI):m/z535[M+1]+。
1H-NMR(400MHz,DMSO):δppm 8.81(s,1H),8.20(s,1H),7.69(brs,1H),7.49(brs,1H)7.26(d,J=4Hz,1H),7.21-7.19(m,1H),6.76-6.73(m,1H),5.46(s,2H),4.64-4.59(m,2H),3.72-3.65(m,2H),3.13(t,J=4Hz,4H),2.44(t,J=4Hz,4H),2.21(s,3H).
Example 2: preparation of Compound 2
The structural formula of the compound 2 is as follows:
the synthetic route for compound 2 is:
The specific preparation method of the compound 2 comprises the following steps:
the first step: synthesis of Compound 2B
Compound 2A (8.0 g,34.3 mmol) was dissolved in DCM (100.0 mL), and tetrahydropyrrole (1.22 g,17.2 mmol) was added dropwise under ice-bath, and stirred at room temperature for 2 hours. Then benzaldehyde is added dropwise in ice bath, and the mixture is stirred for 36 hours after being warmed to room temperature. TLC showed that after the reaction was completed, the reaction solution was dried by spin-drying, and the residue was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate=3/1 (volume ratio)) to give compound 2B (6.6 g, yellow oil, yield: 60%).
MS(ESI):m/z 322[M+1]+。
1H NMR(400MHz,CDCl3)δppm 7.45-7.25(m,11H),5.22(s,2H),4.75(s,2H),3.78-3.76(m,2H),2.75-2.52(m,2H).
And a second step of: synthesis of Compound 2C
Compound 2B (6 g,18.7 mmol) was dissolved in THF (80 mL), a 1.0M solution of LiHMDS in THF (28 mL,28 mmol) was added dropwise at-60℃and stirred at-60℃for 1 hour, followed by a solution of diethyl oxalate (4.1 g,28 mmol) in THF (6 mL). The reaction was slowly warmed to room temperature and stirred for 12 hours. TLC showed that after the reaction was completed, ethyl acetate and water were added, extraction was performed, the organic phase was washed with brine, and the residue was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate=3/1 (volume ratio)) to give compound 2C (5 g, yellow solid, yield: 64%).
MS(ESI):m/z 422[M+1]+。
And a third step of: synthesis of Compound 2D
Compound 2C (5 g,11.86 mmol) was dissolved in methanol (30 mL), THF (30 mL) and acetic acid (6 mL), and compound 1D-1 (0.9 g,11.86 mmol) was added dropwise under ice-bath and stirred at room temperature for 16 hours. TLC showed that after the reaction was completed, most of the methanol was removed by rotation, ethyl acetate and water were added, extraction was performed, the organic phase was washed with saturated sodium bicarbonate and brine, and the residue was purified by beating (petroleum ether/ethyl acetate=1/1, 40 ml) to give compound 2D (4.0 g, white solid, yield: 73%).
MS(ESI):m/z 462[M+1]+。
Fourth step: synthesis of Compound 2E
Compound 2D (4.0 g,8.67 mmol) was dissolved in acetonitrile (80 mL) and water (20 mL), ruthenium trichloride hydrate (0.19 g,0.87 mmol) and sodium periodate (2.4 g,10.4 mmol) were added while ice-cooling, and stirred for 4h at room temperature. After TLC showed that acetonitrile was removed by spin, ethyl acetate and water were added, the organic phase was extracted, washed with brine, spin-dried, and the residue was purified by column chromatography on silica gel (eluent: petroleum ether/ethyl acetate=1/1 (volume ratio)) to give compound 2E (2 g, pale yellow oil, yield: 60%).
MS(ESI):m/z 388[M+1]+。
1H NMR(400MHz,CDCl3)δppm 7.41-7.25(m,5H),5.24(s,2H),5.00(s,2H),4.75-4.71(m,2H),4.48-4.45(m,2H),4.32(s,2H),4.10-4.05(m,2H),1.45-1.40(m,3H).
Fifth step: synthesis of Compound 2F
Compound 2E (1.0 g,2.58 mmol) was dissolved in DMF (12 mL) and then DMF-DMA (6 mL) was added and stirred at 110℃for 2h. After completion of TLC, the reaction solution was dried by spin to give compound 2F (1.1 g, brown yellow oil, yield: 96%), and the crude product was used directly in the next step.
MS(ESI):m/z 443[M+1]+。
Sixth step: synthesis of Compound 2G
Compound 2F (1.1 g,2.49 mmol) was dissolved in DMF (15 mL) and then INT-1 (0.29 g,2.49 mmol) and potassium carbonate (1.03 g,7.46 mmol) were added and stirred at 100deg.C for 3 days. After TLC showed that ethyl acetate and water were added, extraction was performed, the organic phase was washed with brine, dried by spin-drying, and the residue was purified by silica gel column chromatography (eluent: ethyl acetate/methanol=10/1 (volume ratio)) to give compound 2G (0.55G, brown oil, purity: 60%, yield: 19%).
MS(ESI):m/z 697[M+1]+。
Seventh step: synthesis of Compound 2H
Compound 2G (0.55G, 60% purity, 0.47 mmol) was dissolved in NMP (8 mL) and then 30% ammonia in methanol (8 mL) was added and stirred at 100deg.C for 3 days. After TLC showed that it was completed, it was dried by spin-drying, and the residue was purified by silica gel column chromatography (eluent: ethyl acetate/methanol=10/1 (volume ratio)) to give compound 2H (0.4 g, brown oil, purity: 50%, yield: 63%).
MS(ESI):m/z 668[M+1]+。
Eighth step: synthesis of Compound 2
Compound 2H (100 mg,0.07 mmol) was dissolved in methanol (4 mL), then 10% wet palladium on carbon (10 mg), hydrogen balloon was substituted for the gas, and stirred at room temperature for 16 hours. TLC showed that after the reaction was complete, filtration, spin-drying and purification of the residue by HPLC (Waters Sunfire OBD 100X30mm,5 μm, mobile phase A: 0.1% TFA in water, mobile phase B: acetonitrile, gradient: 10% acetonitrile in 1min,52% -52% acetonitrile to 10min,95% acetonitrile to 14min,10% acetonitrile to 16min end) gave compound 2 (15 mg, yellow solid, yield: 38%).
MS(ESI):m/z 534[M+1]+。
1H NMR(400MHz,DMSO)δppm 9.67(s,1H),9.33(s,1H),7.98(s,1H),7.68(s,1H),7.30-7.21(m,2H),6.86(dd,J=9.2,2.9Hz,1H),4.90-4.82(m,2H),4.66(s,1H),3.75(d,J=4.8Hz,2H),3.20-3.10(m,4H),2.46-2.40(m,4H),2.20(s,3H).
Example 3: preparation of Compound 3
The structural formula of the compound 3 is as follows:
the synthetic route for compound 3 is:
The specific preparation method of the compound 3 comprises the following steps:
The first step: synthesis of Compound 3B
The hydrochloride salt of compound INT-2 (0.4 g,1 mmol) was added to DMF (6 mL) at room temperature, and 3A (0.35 g,1.1mmol, synthesized by the procedure and method described on pages 42-44 of WO 200874788) and potassium carbonate (0.28 g,2 mmol) were added at room temperature. Then heated to 100 ℃ and reacted for 48 hours. TLC showed that after the reaction was completed, the reaction solution was diluted with water, extracted with ethyl acetate, washed with brine, the organic phase was dried over anhydrous sodium sulfate, and the residue was purified by silica gel column chromatography (eluent: ethyl acetate/methanol=5:1 (volume ratio)), to give compound 3B (0.3 g, brown oil, yield 29%)
MS(ESI):m/z602.2[M+1]+。
And a second step of: synthesis of Compound 3
Compound 3B (300 mg,60% purity, 0.3 mmol) was added to a jar containing NMP (5 mL) at room temperature, followed by 7M NH3 in methanol (5 mL). Then heated to 95℃and reacted for 3 days. TLC showed that after the reaction was completed, methanol, ethyl acetate and water were diluted, extracted, dried, and the residue was purified by HPLC (Waters Sunfire OBD X30mm,5 μm, mobile phase A: 0.1% TFA in water, mobile phase B: acetonitrile, gradient: 10% acetonitrile running 1min,52% -52% acetonitrile running 10min,95% acetonitrile running 14min,10% acetonitrile running 16min ended) to give compound 3 (20 mg, pale yellow solid, purity 90%, yield 12%).
MS(ESI):m/z573.2[M+1]+。
1H-NMR(400MHz,DMSO-d6):δppm8.89(s,1H),8.24(s,1H),7.49(brs,1H),7.29(brs,1H),7.23(d,J=4Hz,1H),7.19(d,J=8Hz,1H),6.78(dd,J=8Hz,4Hz,1H),4.64-4.61(m,2H),3.64-3.61(m,2H),3.08(t,J=4Hz,4H),2.97(t,J=8Hz,2H),2.93(s,4H),2.79(t,J=8Hz,2H),2.22(s,3H),1.74(t,J=4Hz,4H).
Example 4: preparation of Compound 4
The structural formula of the compound 4 is as follows:
The synthetic route for compound 4 is:
The specific preparation method of the compound 4 comprises the following steps:
the first step: synthesis of Compound 4B
Compound 4A (10.0 g,71.3 mmol) was dissolved in DMF (100 mL), DMF-DMA (30 mL) was added dropwise, and the mixture was warmed to 120℃and stirred for 2h. TLC showed that after the reaction was completed, the reaction solution was cooled to room temperature and dried by spin-drying to give compound 4B (10.0 g, brown oil, yield: 72%) which was used in the next step without further purification.
MS(ESI):m/z 196.1[M+1]+。
And a second step of: synthesis of Compound 4C
Compound 4B (10.0 g,51.2 mmol) was dissolved in methanol (100 mL) and acetic acid (10 mL), and compound 1D-1 (3.9 g,51.2 mmol) was added dropwise and stirred at room temperature for 12h. TLC showed that after the reaction was completed, methanol was swirled off, water (200 mL) was added, and extracted with ethyl acetate (60 mL. Times.2), the organic phases were combined, washed successively with saturated sodium hydrogencarbonate (60 mL. Times.1) and saturated aqueous sodium chloride (60 mL. Times.1), the organic phase was dried over anhydrous sodium sulfate, and the obtained residue was purified by column chromatography on silica gel (eluent: petroleum ether/ethyl acetate=2/1 (volume ratio)) to give compound 4C (2.2 g, pale yellow solid, yield: 24%).
MS(ESI):m/z 181[M+1]+。
And a third step of: synthesis of Compound 4D
Compound 4C (1.8 g,9.99 mmol) was dissolved in acetonitrile (30 mL), NBS (2.13 g,11.99 mmol) was added in portions under ice bath, and the mixture was stirred at 50℃for 4 hours. TLC showed that after the reaction was completed, most of acetonitrile was swirled off, water (100 mL) was added, and extracted with ethyl acetate (30 ml×2), and after the organic phases were combined, washed with saturated sodium bicarbonate (30 ml×1) and saturated aqueous sodium chloride (30 ml×1) in this order, the organic phase was dried over anhydrous sodium sulfate, and the residue was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate=3/1 (volume ratio)) to give compound 4D (2.0 g, pale yellow solid, yield: 77%).
MS(ESI):m/z 259.0[M+1]+,261.0[M+3]+。
1H NMR(400MHz,CDCl3)δppm 4.71-4.65(m,2H),4.08-3.95(m,2H),2.69(t,J=6.1Hz,2H),2.63-2.56(m,2H),2.53(s,1H),2.22-2.11(m,2H).
Fourth step: synthesis of Compound 4E
Compound 4D (2.0 g,7.72 mmol) was dissolved in DMF (25 mL) and then DMF-DMA (10 mL) was added and stirred at 120℃for 1h. After completion of TLC, the reaction solution was dried by spin to give compound 4E (2.4 g, brown yellow oil, yield: 99%), and the crude product was used in the next step.
MS(ESI):m/z 314.0[M+1]+,316.0[M+3]+。
Fifth step: synthesis of Compound 4F
Compound 4E (2.4 g,7.64 mmol) was dissolved in DMF (30 mL) and then added to compound INT-1 (2.42 g,7.64 mmol) and DIPEA (1.97 g,15.28 mmol) for 16h at 100deg.C. After TLC showed that water (100 mL) was added and extracted with ethyl acetate (30 ml×2), the organic phases were combined, washed with saturated aqueous sodium chloride (30 ml×1), dried over anhydrous sodium sulfate, and the organic phase was dried by spin-drying, and the residue was purified by silica gel column chromatography (eluent: ethyl acetate/methanol=10/1 (volume ratio)) to give compound 4F (1.0 g, pale yellow solid, yield: 23%).
MS(ESI):m/z 568.1[M+1]+,570.1[M+3]+。
Sixth step: synthesis of Compound 4
Compound 4F (100 mg,0.18 mmol) was dissolved in dioxane (2.0 mL), then compound 4F-1 (25 mg,0.26 mmol), cesium carbonate (115 mg,0.35 mmol), pd 2(dba)3 (16 mg,0.02 mmol), xantphos (20 mg,0.04 mmol) was added and the reaction stirred under nitrogen at 110℃for 16 hours. TLC showed that after the reaction was completed, ethyl acetate and water were added, the organic phase was washed with brine, dried by spin, and the residue was purified by HPLC (Waters Sunfire OBD X30mm,5 μm, mobile phase A: 0.1% TFA in water, mobile phase B: acetonitrile, gradient: 10% acetonitrile to 1min,52% -52% acetonitrile to 10min,95% acetonitrile to 14min,10% acetonitrile to 16min end), to give compound 4 (6.6 mg, white solid, yield: 6%).
MS(ESI):m/z 581[M+1]+。
1H NMR(400MHz,DMSO)δppm 8.74(s,1H),8.26(s,1H),7.27(d,J=2.4Hz,1H),7.18(d,J=7.9Hz,1H),6.75(dd,J=9.1,2.9Hz,1H),4.61-4.35(m,3H),3.60-3.56(m,2H),3.28-3.24(m,5H),3.15-3.09(m,4H),2.72(t,J=7.3Hz,2H),2.45-2.40(m,4H),2.20(s,3H).
Example 5: preparation of Compound 5
The structural formula of the compound 5 is as follows:
synthesis of Compound 5 was synthesized by the step of synthesizing Compound 4 in reference example 4, in which zinc cyanide was used in place of Compound 4F-1 in the sixth step.
MS(ESI):515.2[M+1]+。
1H NMR(400MHz,DMSO)δ(ppm)9.44(s,1H),9.16(s,1H),8.40(s,1H),7.34-7.16(m,2H),6.95-6.77(m,1H),4.78-4.72(m,2H),3.98-3.95(m,2H),3.35-3.29(m,8H),2.86-2.62(m,7H).
Example 6: preparation of Compound 6
The structural formula of the compound 6 is as follows:
Synthesis of Compound 6 reference the step of synthesizing Compound 4 in example 4, wherein in the sixth step, compound 4F-1 is replaced with phosphorus oxide dimethyl, compound 6 is synthesized.
MS(ESI):566.2[M+1]+。
1H NMR(400MHz,DMSO)δ(ppm)8.90(s,1H),8.33(s,1H),7.25-7.15(m,2H),6.78(dd,J=9.1,2.7Hz,1H),4.66-4.54(m,3H),3.63-3.53(m,2H),3.15-3.09(m,4H),2.95-2.75(m,4H),2.42(s,4H),2.20(s,3H),1.68(s,3H),1.63(s,3H).
Example 7: preparation of Compound 7
The structural formula of the compound 7 is as follows:
Synthesis of Compound 7 reference example 4 the step of synthesizing Compound 4 in which Compound 4F-1 was replaced with acetamide in the sixth step, compound 7 was synthesized.
MS(ESI):547.2[M+1]+。
Experimental example 1: anti-proliferative Activity test of the inventive Compounds against HT29 cells
Experimental materials:
McCoy's 5A medium, penicillin/streptomycin antibiotics were purchased from vitamin, and fetal bovine serum was purchased from Biosera. CellTiter-Glo (cell viability chemiluminescent detection reagent) reagent was purchased from Promega. HT29 cell line was purchased from the marsupenario life technologies Co. Nivo Multilabel Analyzer (Perkinelmer).
The experimental method comprises the following steps:
HT29 cells were seeded in white 96-well plates, 80 μl of cell suspension per well, containing 3000 HT29 cells. Cell plates were placed in a carbon dioxide incubator overnight for culture.
The test compounds were diluted 3-fold to the 9 th concentration, i.e. from 0.6mM to 91.45nM, using a row gun and a double multiplex assay was set up. 78. Mu.L of medium was added to the intermediate plate, and 2. Mu.L of the gradient diluted compound per well was transferred to the intermediate plate at the corresponding position, and 20. Mu.L of the gradient diluted compound per well was transferred to the cell plate after mixing. The concentration of compound transferred into the cell plate ranged from 3. Mu.M to 0.457nM. The cell plates were placed in a carbon dioxide incubator for 3 days. A cell plate was also prepared and the signal value read on the day of dosing as the maximum value (Max value in the following equation) was used in the data analysis. To this plate, 25. Mu.L of cell viability chemiluminescent detection reagent was added per well and incubated at room temperature for 10 minutes to stabilize the luminescent signal. Multiple marker analyzer readings were used.
To the cell plate, 25. Mu.L of a cell viability chemiluminescent detection reagent per well was added, and the luminescent signal was stabilized by incubation at room temperature for 10 minutes. Multiple marker analyzer readings were used.
Data analysis:
The raw data is converted to inhibition rate using equation (Sample-Min)/(Max-Min) ×100%, and the IC50 values can be obtained by curve fitting four parameters (obtained in "log (inhibitor) vs. response-Variable slope" mode in GRAPHPAD PRISM). Table 1 provides the inhibitory activity of the compounds of the invention on HT29 cell proliferation.
TABLE 1 anti-cell proliferation Activity data (IC 50) for the compounds of the invention
From the experimental results in table 1, it can be seen that the compounds of the present invention have good activity in inhibiting HT29 cell proliferation. Compound 1 had an activity of less than 100nM. Showing extremely important antitumor potential.
Experimental example 2: PLK1 enzyme Activity test experiment
This assay was used to examine the efficacy of compounds to inhibit PLK1 enzymatic activity, with lower IC 50 values indicating high efficacy of compounds as PLK1 inhibitors in the following assay settings.
Experimental materials:
PLK1 Active was purchased from CARNA;
Casein Protein is available from SIGNALCHEM;
ADP-Glo KINASE ASSAY was purchased from Promega;
KINASE ASSAY buffer III was purchased from SIGNALCHEM;
Nivo Multilabel Analyzer (Perkinelmer).
The experimental method comprises the following steps:
the enzyme, substrate, ATP and inhibitor were diluted using a kinase buffer in the kit.
The test compound was diluted to 1mM with 100% DMSO as the first concentration, and then 5-fold diluted to the 8 th concentration with a row gun,
I.e., from 1mM to 0.013. Mu.M. Compound working solutions containing 5% dmso were prepared by diluting each concentration point of the compound 20-fold with 1X kinase buffer, and 1 μl of each concentration gradient working solution of the compound was added to the microplates to set up double wells. To the microplate was added 2. Mu.l PLK1 enzyme (15 ng), 2. Mu.l of a mixture of substrate and ATP (20. Mu.M ATP, 0.2. Mu.g/. Mu.l Casein protein) at a final concentration gradient of 10. Mu.M diluted to 0.13nM and the reaction was allowed to react at 25℃for 60 minutes. After the reaction was completed, 5. Mu.l of ADP-Glo reagent was added to each well, the reaction was continued at 25℃for 40 minutes, 10. Mu.l of the kinase detection reagent was added to each well after the completion of the reaction, and after 30 minutes of the reaction at 25℃the chemiluminescence was read by using a PERKINELMER NIVO-multiple-tag analyzer, and the integration time was 0.5 seconds.
Max wells positive control wells read no enzyme blank wells
Min well: negative control wells read as wells containing 1% dmso solvent
Data analysis:
The raw data is converted to inhibition rate using the equation (Sample-Min)/(Max-Min) ×100%, and the value of IC 50 can be obtained by curve fitting four parameters (log (inhibitor) vs. response-Variable slope mode in GRAPHPAD PRISM).
Wherein the inhibition effect of the PLK1 enzyme inhibitor NMS-1286937 prepared by the invention on PLK1 enzyme activity is shown in table 2.
TABLE 2 IC 50 data for PLK1 enzyme inhibition by the compounds of the invention
Numbering of compounds | IC50(nM) |
NMS-1286937 | 4.60 |
Compound 1 | 17.20 |
As shown in Table 2, the compound of the invention, specifically compound 1, has a better inhibition effect on PLK1 enzyme, the activity reaches nM level, and compared with clinical compound NMS-1286937, the compound has only three to four times of gap, is an extremely excellent lead compound, has great potential to further optimize the structure, obtains better compound structure and generates good clinical application prospect.
While embodiments of the present invention have been illustrated and described above, it will be appreciated that the above described embodiments are illustrative and should not be construed as limiting the invention. Variations, modifications, substitutions, and alterations are also possible in the above described embodiments without departing from the principles and spirit of the invention, and such variations, modifications, substitutions, and alterations are to be within the scope of this disclosure.
Claims (4)
1. A tri-fused ring compound characterized in that the compound is a compound shown as a formula 4, a formula 6 or a formula 7 or a pharmaceutically acceptable salt thereof or a stereoisomer thereof,
。
2. A pharmaceutical composition comprising an effective amount of a compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof, or one or more stereoisomers thereof.
3. The pharmaceutical composition according to claim 2, wherein the pharmaceutical composition further comprises at least one pharmaceutically acceptable excipient.
4. Use of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a pharmaceutical composition according to claim 2, for the manufacture of a medicament for the treatment and/or prophylaxis of cancer; the cancer is any one or more of hematological tumor, pancreatic cancer, colorectal cancer and lung cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020115669678 | 2020-12-25 | ||
CN202011566967 | 2020-12-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114685520A CN114685520A (en) | 2022-07-01 |
CN114685520B true CN114685520B (en) | 2024-08-30 |
Family
ID=82135913
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111602260.2A Active CN114685520B (en) | 2020-12-25 | 2021-12-24 | Tri-fused ring compound and pharmaceutical composition and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114685520B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118382626A (en) * | 2021-12-10 | 2024-07-23 | 山东绿叶制药有限公司 | Protein kinase inhibitor and preparation method and application thereof |
WO2024153110A1 (en) * | 2023-01-17 | 2024-07-25 | 北京哲源科技有限责任公司 | Stereoisomer and deuterated derivative of pyrazoloquinazoline compound and use |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101563351A (en) * | 2006-12-21 | 2009-10-21 | 内尔维阿诺医学科学有限公司 | Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors |
CN102076689A (en) * | 2008-06-26 | 2011-05-25 | 内尔维阿诺医学科学有限公司 | Pyrazolo-quinazolines |
CN102079746A (en) * | 2003-05-22 | 2011-06-01 | 内尔维阿诺医学科学有限公司 | Pyrazolo-quinazoline derivatives,process for their preparation and their use as kinase inhibitors |
CN103339134A (en) * | 2011-01-26 | 2013-10-02 | 内尔维阿诺医学科学有限公司 | Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors |
US20130302416A1 (en) * | 2011-01-26 | 2013-11-14 | Nerviano Medical Sciences S.R.L. | Tricyclic derivatives, process for their preparation and their use as kinase inhibitors |
CN107383019A (en) * | 2017-07-28 | 2017-11-24 | 江苏艾凡生物医药有限公司 | Pyrazolo [4,3 h] quinazoline compounds and application thereof |
WO2018086591A1 (en) * | 2016-11-11 | 2018-05-17 | 上海海雁医药科技有限公司 | Pyridinamine-substituted heterotricyclo compounds, preparation thereof, and use in medicines |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109761986B (en) * | 2017-11-10 | 2021-10-08 | 上海翰森生物医药科技有限公司 | Tricyclic derivative inhibitor, preparation method and application thereof |
CN110272416A (en) * | 2018-03-14 | 2019-09-24 | 武汉宇科源医药生物科技有限公司 | Pyrazolo [3,4-c] pyridine -7- amine derivative and its preparation method and application |
-
2021
- 2021-12-24 CN CN202111602260.2A patent/CN114685520B/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102079746A (en) * | 2003-05-22 | 2011-06-01 | 内尔维阿诺医学科学有限公司 | Pyrazolo-quinazoline derivatives,process for their preparation and their use as kinase inhibitors |
CN101563351A (en) * | 2006-12-21 | 2009-10-21 | 内尔维阿诺医学科学有限公司 | Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors |
CN102076689A (en) * | 2008-06-26 | 2011-05-25 | 内尔维阿诺医学科学有限公司 | Pyrazolo-quinazolines |
CN103339134A (en) * | 2011-01-26 | 2013-10-02 | 内尔维阿诺医学科学有限公司 | Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors |
US20130302416A1 (en) * | 2011-01-26 | 2013-11-14 | Nerviano Medical Sciences S.R.L. | Tricyclic derivatives, process for their preparation and their use as kinase inhibitors |
WO2018086591A1 (en) * | 2016-11-11 | 2018-05-17 | 上海海雁医药科技有限公司 | Pyridinamine-substituted heterotricyclo compounds, preparation thereof, and use in medicines |
CN107383019A (en) * | 2017-07-28 | 2017-11-24 | 江苏艾凡生物医药有限公司 | Pyrazolo [4,3 h] quinazoline compounds and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN114685520A (en) | 2022-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111153901B (en) | Nitrogen-containing fused heterocyclic SHP2 inhibitor compound, preparation method and application | |
CN112745335B (en) | Tri-heterocyclic compound and application thereof | |
EA033698B1 (en) | Inhibitors of lysine specific demethylase-1 | |
CN114685520B (en) | Tri-fused ring compound and pharmaceutical composition and application thereof | |
CN112851663B (en) | Parallel heterocyclic compound and application thereof | |
CN112300153B (en) | Heterocyclic compound, pharmaceutical composition and application | |
CN113527299B (en) | Nitrogen-containing condensed ring compound, preparation method and application | |
CN113024544B (en) | Cyano-containing heterocyclic compound and application thereof | |
CN112094269B (en) | Saturated six-membered ring heterocyclic compound, preparation method and application | |
CN112707905B (en) | Tri-heterocyclic compound, preparation method and application thereof | |
CN113939518A (en) | Fused tricyclic compounds as kinase inhibitors | |
CN114805361B (en) | Amino substituted aromatic heterocyclic pyrazole compound, preparation method and application | |
KR20210136995A (en) | Bruton's Tyrosine Kinase Inhibitors | |
CN114685531A (en) | Tetraheterocyclic compounds, pharmaceutical compositions and uses thereof | |
US20240270753A1 (en) | Heterocyclic compound for inhibiting shp2 activity, preparation method therefor and use thereof | |
CN111936144A (en) | JAK inhibitors | |
CN110872285A (en) | Heterocyclic compounds as receptor interacting protein 1(RIP1) kinase inhibitors | |
CN114524810B (en) | Pyrimidine heterocyclic compounds, preparation method and application | |
TW202241413A (en) | Pyrazoloquinazoline compound, and preparation method therefor and use thereof | |
CN110357905B (en) | Macrocyclic derivatives as protein kinase inhibitors, and preparation method and application thereof | |
CN112778336B (en) | Nitrogen-containing condensed ring STING regulator compound, preparation method and application | |
WO2021099832A2 (en) | Adenosine receptor antagonist compounds | |
JP2022538901A (en) | Pyrazolone condensed pyrimidine compound, its production method and use | |
CN115677702B (en) | Tri-fused ring compound and pharmaceutical composition and application thereof | |
CN116655655A (en) | Tetrafused ring compound, and pharmaceutical composition and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |